Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents
Circulation2012Vol. 125(9), pp. 1110–1121
Citations Over TimeTop 1% of 2012 papers
Lorenz Räber, Michael Magro, Giulio Stefanini, Bindu Kalesan, Ron T. van Domburg, Yoshinobu Onuma, Peter Wenaweser, Joost Daemen, Bernhard Meier, Peter Jüni, Patrick W. Serruys, Stephan Windecker
Abstract
Current treatment with EES is associated with a lower risk of very late stent thrombosis compared with early-generation drug-eluting stents.
Related Papers
- → Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report(2013)7 cited
- → Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report(2012)1 cited
- → Long lasting response to second-line everolimus in kidney cancer(2013)
- Neointima Hyperplasia and Angiographic Late Lumen Loss after Sirolimus-Eluting and Zotarolimus-Eluting Stent Implantation in Diabetic Patients. The Diabetes and Drug-Eluting Stent (DiabeDES III) Intravascular Ultrasound and Angiography Trial(2009)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)